What is Sequella?
Sequella operates as a specialized clinical-stage pharmaceutical enterprise dedicated to the discovery and development of innovative antimicrobial therapies. The company focuses on combating drug-resistant bacterial, fungal, and parasitic infections, with a primary emphasis on tuberculosis and its multidrug-resistant variants. By targeting global health threats that affect billions, Sequella has established a significant market footprint. Its core assets, including SQ109 and sutezolid, have successfully navigated phase 2 clinical trials, demonstrating the company's technical proficiency and commitment to addressing the urgent, unmet medical needs in infectious disease management. Through its strategic focus on high-impact therapeutic areas, Sequella remains at the forefront of medical innovation.
How much funding has Sequella raised?
Sequella has raised a total of $11.9M across 11 funding rounds:
Debt
$2M
Multiple Rounds
$1.6M
Unspecified
$100K
Unspecified
$555K
Debt
$3.1M
Private Equity
$1.7M
Private Equity
$630K
Debt (2010): $2M, investors not publicly disclosed
Debt (2011): $1M featuring Easton Capital Partners
Unspecified (2011): $550K backed by Easton Capital Partners
Debt (2011): $50K with participation from Easton Capital Partners
Unspecified (2012): $100K led by Easton Capital Partners
Unspecified (2013): $555K supported by Easton Capital Partners
Debt (2014): $3.1M, investors not publicly disclosed
Private Equity (2016): $1.7M, investors not publicly disclosed
Private Equity (2017): $630K, investors not publicly disclosed
Key Investors in Sequella
Easton Capital Partners
Easton Capital Investment Group manages institutional funds and specializes in early-to-growth stage investments, often leveraging strategic co-investment relationships to support its portfolio companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Sequella?
With the recent strategic investment, Sequella is well-positioned to accelerate its late-stage clinical development programs. The company's roadmap involves advancing its lead candidates through the final regulatory hurdles required for market entry. By prioritizing the refinement of its antibiotic portfolio, Sequella aims to mitigate the global burden of resistant infections, particularly in underserved regions. Future growth will likely center on scaling manufacturing capabilities and fostering collaborative partnerships to ensure the widespread distribution of its life-saving treatments. As the company transitions from a research-heavy entity to a commercial-stage organization, the focus will remain on maintaining high-efficacy standards while navigating the complex landscape of global pharmaceutical regulation.
See full Sequella company page
